Expertise in
10
conditions

Dr. Hyo S. Han

Oncology
Moffitt Cancer Center, Richard M. Schulze Family Foundation Outpatient Center At McKinley Campus
10920 McKinley Dr, 
Tampa, FL 
Accepting New Patients
Offers Telehealth
Expertise in
10
conditions
Moffitt Cancer Center, Richard M. Schulze Family Foundation Outpatient Center At McKinley Campus
10920 McKinley Dr, 
Tampa, FL 

Overview

Hyo Han is an Oncologist practicing medicine in Tampa, Florida.

Dr. Han is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer, and Paget Disease of the Breast.

She is actively involved in clinical research, co-authoring 94 peer reviewed articles and participating in 8 clinical trials. Dr. Han is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in FL

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Moffitt Cancer Center, Richard M. Schulze Family Foundation Outpatient Center at McKinley Campus
10920 McKinley Dr, Tampa, FL 33612

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Atezolizumab, Olaparib
Study Phase: Phase 2
A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer
A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2026
Intervention Type: Drug
Study Drugs: LEE011, Letrozole, BYL719
Study Phase: Phase 1/Phase 2
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 06, 2026
Intervention Type: Biological
Study Drugs: DC1 Vaccine, WOKVAC Vaccine
Study Phase: Phase 2
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Enrollment Status: Terminated
Publish Date: March 23, 2022
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Carboplatin
Study Phase: Phase 2
A Phase 1 Study of TPI 287 Concurrent With Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases From Advanced Breast and Non-Small Cell Lung (NSCL) Cancer
A Phase 1 Study of TPI 287 Concurrent With Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases From Advanced Breast and Non-Small Cell Lung (NSCL) Cancer
Enrollment Status: Terminated
Publish Date: February 04, 2021
Intervention Type: Drug, Procedure
Study Phase: Phase 1
Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer
Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer
Enrollment Status: Completed
Publish Date: February 04, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I-II Study of PTX-200 Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Metastatic and Locally Advanced Breast Cancer
A Phase I-II Study of PTX-200 Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Metastatic and Locally Advanced Breast Cancer
Enrollment Status: Terminated
Publish Date: September 24, 2020
Intervention Type: Drug, Other, Procedure
Study Phase: Phase 1/Phase 2
View 7 Less Clinical Trials

94 Total Publications

Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.
Journal: JAMA oncology
Published: July 30, 2026
Similar Doctors
Expertise in
30
conditions
Expertise in
30
conditions
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (1.1 miles away)
813-934-6811
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Philippe Spiess is an Oncologist practicing medicine in Tampa, Florida. Dr. Spiess is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Penile Cancer, Muscle Invasive Bladder Cancer, Bladder Cancer, Nephrectomy, and Penectomy. Dr. Spiess is currently accepting new patients.

Expertise in
37
conditions
Expertise in
37
conditions
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (1.1 miles away)
888-663-3488
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Julio Chavez is an Oncologist practicing medicine in Tampa, Florida. Dr. Chavez is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Aspiration. Dr. Chavez is currently accepting new patients.

Expertise in
55
conditions
Dr. Lubomir Sokol
Hematology | Oncology
Expertise in
55
conditions
Dr. Lubomir Sokol
Hematology | Oncology
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (1.1 miles away)
813-692-4147
Languages Spoken:
English, Czech, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

Lubomir Sokol is a Hematologist and an Oncologist practicing medicine in Tampa, Florida. Dr. Sokol is highly rated in 55 conditions, according to our data. His clinical expertise encompasses T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Sokol is currently accepting new patients.

Frequently Asked Questions about Dr. Hyo S. Han

How do I make an appointment with Dr. Hyo S. Han?

You can book an appointment with Dr. Hyo S. Han by calling their office at 813-692-4306. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Hyo S. Han a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Hyo S. Han is classified as an Elite expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Hyo S. Han specialize in?

While Dr. Hyo S. Han is a Oncology, they have specific expertise in Breast Cancer, HER-2 Positive Breast Cancer, and Inflammatory Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Hyo S. Han participate in research or clinical trials?

Yes. Dr. Hyo S. Han has published 94 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Hyo S. Han's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Hyo S. Han accept my insurance?

Dr. Hyo S. Han accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 813-692-4306 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Han's expertise for a condition
ConditionClose
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile